Program
dexmethylphenidate
Also written as “Dexmethylphenidate Hydrochloride”, “CTx-1301 - Dexmethylphenidate 37.5mg” and “Dexmethylphenidate”.
Its studies are mostly in Attention Deficit Disorder with Hyperactivity · Fasting · Fatigue, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Cingulate Therapeutics | 60 open or running | phase 3since Mar 1, 2022 | Sep 19, 2019 | none ahead |
| Novartis | 50 open or running | phase 4since Nov 27, 2007 | Aug 30, 2005 | none ahead |
| Teva Pharmaceutical Industries | 20 open or running | phase 1since Jan 26, 2009 | Jan 26, 2009 | none ahead |
| Bristol-Myers Squibb | 10 open or running | phase 2since Oct 8, 2002 | Oct 8, 2002 | none ahead |
Also a collaborator on its studies: rho-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 8, 2002First study: phase 2 study in FatigueNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT00047476 · 160 enrolled · United States
- Aug 30, 2005Novartis's first studies: 2 phase 3 studies in Attention Deficit Disorder with HyperactivityNew to NovartisNovartis · NCT00141063, NCT00141050
- Mar 8, 2006Phase 3 study in Attention Deficit Disorder with HyperactivityNovartis · NCT00301236 · 252 enrolled · United States
- Nov 27, 2007Phase 4 study in Attention Deficit Disorder with HyperactivityNovartis · NCT00564954 · 86 enrolled · United States
- Oct 16, 2008Phase 4 study in Attention Deficit Disorder with HyperactivityNovartis · NCT00776009 · 165 enrolled · United States
- Jan 26, 2009Teva Pharmaceutical Industries's first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00829712, NCT00829673
- Sep 19, 2019Cingulate Therapeutics's first study: phase 2 study in Attention Deficit Disorder with HyperactivityNew to Cingulate TherapeuticsCingulate Therapeutics · NCT04138498 · 45 enrolled · United States
- Jun 24, 2020Phase 1 study in FastingCingulate Therapeutics · NCT04449250 · 27 enrolled · United States
- Mar 1, 2022Phase 3 study in Attention Deficit Disorder with HyperactivityCingulate Therapeutics · NCT05286762 · 103 enrolled · United States
- Nov 14, 2022Phase 3 study in Attention Deficit Disorder with HyperactivityCingulate Therapeutics · NCT05631626 · 26 enrolled · United States
- Jun 21, 2023Phase 3 study in Attention Deficit Disorder with HyperactivityCingulate Therapeutics · NCT05924594 · 45 enrolled · United States
- Apr 25, 2025Phase 1 study in FastingCingulate Therapeutics · NCT07119073 · 25 enrolled · United States
TargetBeta
“Dopamine transporter inhibitor; Norepinephrine transporter inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lisdexamfetaminerule | Takeda | phase 4 | 47 |
| Bupropionrule | GlaxoSmithKline | phase 4 | 29 |
| Amphetaminerule | Tris Pharma | phase 4 | 8 |
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07119073Fasting · United States | 1 | Completed | Cingulate Therapeutics | Dec 21, 2024 | 25 |
| NCT05924594Attention Deficit Disorder with Hyperactivity · United States | 3 | Suspended | Cingulate Therapeutics | Feb 2027 | 45 |
| NCT05631626Attention Deficit Disorder with Hyperactivity · United States | 3 | Completed | Cingulate Therapeutics | Jun 13, 2023 | 26 |
| NCT05286762Attention Deficit Disorder with Hyperactivity · United States | 3 | Completed | Cingulate Therapeutics | Feb 29, 2024 | 103 |
| NCT04449250Fasting · United States | 1 | Completed | Cingulate Therapeutics | Oct 14, 2022 | 27 |
| NCT04138498Attention Deficit Disorder with Hyperactivity · United States | 2 | Completed | Cingulate Therapeutics | Mar 6, 2020 | 45 |
| NCT00829712Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jun 2004 | 24 |
| NCT00829673Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jun 2004 | 24 |
| NCT00776009Attention Deficit Disorder with Hyperactivity · United States | 4 | Completed | Novartis | Dec 2008 | 165 |
| NCT00564954Attention Deficit Disorder with Hyperactivity · United States | 4 | Completed | Novartis | Nov 2007 | 86 |
| NCT00301236Attention Deficit Disorder with Hyperactivity · United States | 3 | Completed | Novartis | 252 | |
| NCT00141063Attention Deficit Disorder with Hyperactivity · United States | 3 | Completed | Novartis | 90 | |
| NCT00141050Attention Deficit Disorder with Hyperactivity · United States | 3 | Completed | Novartis | 90 | |
| NCT00047476Fatigue · United States | 2 | Completed | Bristol-Myers Squibb | 160 |
How it is read
Names in the registry
- “Dexmethylphenidate Hydrochloride”, 4 entries
- “CTx-1301 - Dexmethylphenidate 37.5mg”, 2 entries
- “Dexmethylphenidate”, 2 entries
- “Focalin XR”, 2 entries
- “CTx-1301 - Dexmethylphenidate 25mg”, 1 entry
Codes read as this program: CTX1301.
Conditions, from the studies’ own filings
- Attention Deficit Disorder with Hyperactivity, 9 studies
- Fasting, 2 studies
- Fatigue, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.